CellFE, a leader in non-viral gene editing technology, and Syenex, a pioneer in enveloped delivery vectors, have announced an innovative collaboration to create a hybrid workflow that seamlessly integrates non-viral and viral approaches to cell therapy engineering. This next-generation process aims to enable streamlined workflows of complex edited cells for biotech and pharmaceutical applications.
The collaboration application note will be officially unveiled the week of the highly anticipated J.P. Morgan Healthcare Conference in San Francisco this January, a premier event that brings together industry leaders, investors, and innovators from around the world.
“The market has been anticipating a solution that seamlessly integrates non-viral knockout with viral knockin capabilities into a streamlined workflow—one that preserves cell viability and functionality without compromise.” said Dr. Alla Zamarayeva, CEO of CellFE. “By collaborating with Syenex, we are directly addressing this critical need.”
Also Read: A2 Biotherapeutics Raises $80M to Advance Tmod™ Therapies
Jay Rosanelli, CEO at Syenex, added: “This joint effort showcases the role of collaborative science in accelerating the creation of life-changing medicines for patients around the globe. We are thrilled to partner with CellFE and showcase the potential of this novel hybrid workflow to dramatically simplify manufacturing of genetic medicines.”
This collaboration comes at a pivotal time as allogeneic and autologous cell therapy providers seek more efficient manufacturing processes. A key challenge is developing gentler yet highly effective techniques for delivering gene-editing cargo to patient cells, as current methods—often involving viral transduction and electroporation—can be detrimental to cells and extend recovery and processing times, particularly for complex, sequential editing. This innovative hybrid workflow aims to overcome these challenges, enabling advanced genetic editing while preserving cell functionality and supporting streamlined workflows.
Source: PRNewswire